- 中文名稱
Anti-Human FGFR-4
- 英文名字
- Anti-Human FGFR-4
- 供應商
- ReliaTech
- 產品貨號
- 101-M418
- 產品報價
- ￥詢價/100ug
- 產品說明書
- 點擊查看
- 購買方式
- 90%產品中國有現貨庫存。銀行轉賬、電匯、支票、現金，在線支付寶及網銀支付，或直接與我們電話聯系400-6800-868
- 產品新聞
- 背景資料
- Fibroblast growth factor receptor 4 (FGF R4), also known as CD334, is a 110 kDa glycosylated transmembrane receptor tyrosine kinase. Mature human FGF R4 consists of a 348 amino acid (aa) extracellular domain (ECD) with three Ig-like domains, a 21 aa transmembrane segment, and a 412 aa cytoplasmic domain that contains the tyrosine kinase domain. Within the ECD, human FGF R4 shares 90% and 88% aa sequence identity with mouse and rat FGF R4, respectively. Alternate splicing generates a potentially secreted isoform with a substitution encompassing the transmembrane segment. A 65 kDa N-terminally truncated isoform lacks the signal peptide and first two Ig-like domains. This isoform is produced in human pituitary adenomas and is constitutively phosphorylated and oncogenic. FGF R4 is widely expressed during embryonic development and in adult liver, kidney, and lung. It binds FGF acidic, FGF basic, FGF8, 15, and 19. FGF R4 associates with betaKlotho and sulfated glycosaminoglycans, and these interactions increase the affinity of FGF R4 for its ligands as well as its signaling capacity. FGF19 induced signaling through FGF R4 is important for the regulation of bile acid synthesis and lipid and glucose homeostasis. FGF R4 supports glucose tolerance and insulin sensitivity and protects against hyperlipidemia. It is downregulated in the liver during fasting and is upregulated by insulin. It can exert either proliferative or apoptotic effects on hepatocytes. FGF R4 signaling is additionally required for skeletal muscle development in limbs. FGF R4 interacts in cis with cell surface MMP14, leading to downregulation of both proteins.
- 應用類型
- WB
- 免疫原
- 該Anti-Human FGFR-4的詳細信息查看ReliaTech提供的產品說明書。
- 來源宿主
- 該Anti-Human FGFR-4的詳細信息查看ReliaTech提供的產品說明書。
- 反應性
- 該Anti-Human FGFR-4的詳細信息查看ReliaTech提供的產品說明書。
- 保存建議
- 該Anti-Human FGFR-4的詳細信息查看ReliaTech提供的產品說明書。溶解建議：Centrifuge vial prior to opening. Reconstitute the antibody with 500 μl sterile PBS and the final concentration is 200 μg/ml.
- 其他
- ReliaTech全稱為受體配體技術有限公司 (Receptor Ligand Technologies GmbH)，1999年成立，總部位于德國不倫瑞克，是一家后基因組生物技術公司。ReliaTech主要專注于受體和配體的發現與研究。此外，ReliaTech也開發應用于血管與淋巴管生成研究的相關高品質試劑。目前ReliaTech提供近2800款產品，產品線主要包括重組蛋白(細胞因子、生長因子、可溶性受體)、抗體、ELISA試劑盒等。
- 注意
-
該頁面的中文產品信息的翻譯，僅供參考。準確的產品信息請以廠家的英文說明書為準。下單前，請瀏覽說明書確認。
-
